LAURENCE S. FARER, M.D., M.P.H.; MARY W. LONG; DIXIE E. SNIDER JR., M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor:
"When I use the word relapse," Dr. Buechner said, "it means just what I choose it to mean—neither more nor less."
(With apologies to Lewis Carroll and Humpty Dumpty)
In a recent letter to the editor, Dr. Howard Buechner (1) raised questions about the efficacy of 9-month isoniazid-rifampin tuberculosis chemotherapy regimens recommended by the American Thoracic Society and the Centers for Disease Control (2) and implied that no one has questioned the validity of the trials on which the recommendation was based. In fact, the recommendation was made after a very extensive review and evaluation of the
FARER LS, LONG MW, SNIDER DE. Isoniazid-Rifampin Regimens for Tuberculosis. Ann Intern Med. 1981;95:518–519. doi: 10.7326/0003-4819-95-4-518
Download citation file:
Published: Ann Intern Med. 1981;95(4):518-519.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use